EIKN — Eikon Therapeutics Share News
0.000.00%
Last trade - 00:00- $446.32m
- -$84.86m
Brief: Eikon Therapeutics Announces First Patient Dosed In Teluride-008, A Registrational Phase 2/3 Trial Of Eik1001 In Non-Small Cell Lung Cancer
Brief: Eikon Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results And Provides Clinical And Corporate Updates
Perlmutter-backed Eikon Therapeutics rises as IPO research quiet period ends
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut (updated)